NCT04674839 is a NA clinical trial of MS-20 in Microbiota, sponsored by Microbio Co Ltd.

Who is sponsoring NCT04674839?

NCT04674839 is sponsored by Microbio Co Ltd.

What drugs are being tested in NCT04674839?

Interventions in NCT04674839: MS-20, Placebo.

What condition does NCT04674839 study?

NCT04674839 studies Microbiota.

Is NCT04674839 still recruiting?

NCT04674839 is currently completed. Last updated 23 December 2020.

Last reviewed 2020-12-23 · How we verify

NCT04674839

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals

Completed NA Last updated 23 December 2020

What this trial tests

NA trial testing MS-20 in Microbiota in 100 participants. Completed in 20 November 2020.

Timeline

18 October 2019

Primary endpoint
4 September 2020

20 November 2020

Quick facts

Lead sponsor	Microbio Co Ltd
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	supportive care
Enrollment	100
Start date	18 October 2019
Primary completion	4 September 2020
Estimated completion	20 November 2020
Sites	1 location across Taiwan

Drugs / interventions tested

MS-20 — full drug profile →
Placebo

Conditions studied

Microbiota — all drugs for Microbiota →

Sponsor

Microbio Co Ltd — full company profile →

Who can join

Adults 20 to 65, any sex, with Microbiota. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MicrSoy-20 (MS-20), a fermented soymilk product, has been approved as an Over the counter (OTC) drug in 2011. The therapeutic effect of MS-20 is to ameliorate symptoms such as fatigue and loss of appetite caused by cancer chemotherapy. Animal study revealed orally administration of MS-20 daily for 4 weeks altered the gut microbiota composition in mice. In addition, MS-20 could activate dendritic cell and improve immunotherapy response rate. Thus, it was hypothesis that MS-20 improves host immune activity thus ameliorate fatigue and increase weight is through alteration the gut microbiota composition. In this study, the ability of MS-20 in modulating gut microbiota and the subset of microbiome to be altered by MS-20 was investigated.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Safety assessment of a proprietary fermented soybean solution, Symbiota®, as an ingredient for use in foods and dietary supplements: Non-clinical studies and a randomized trial.
Hung CM, Chu WC, Huang WY, Lee PJ, et al · · 2024 · cited 6× · PMID 38628176 · DOI 10.1002/fsn3.3921
Gut microbes with the <i>gbu</i> genes determine TMAO production from L-carnitine intake and serve as a biomarker for precision nutrition.
Wu WK, Lo YL, Chiu JY, Hsu CL, et al · · 2025 · cited 5× · PMID 39722590 · DOI 10.1080/19490976.2024.2446374

Verify or expand the search:

Other trials of MS-20

Trials testing the same drug.

NCT04909034 — A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembro · NA · completed
NCT04600154 — MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Pancreatic Cancer Patients · NA · unknown

Other recruiting trials for Microbiota

Currently open trials in the same condition.

NCT07479511 — Adaptation of Lung Transplant Recipients at Extreme Altitude · active not recruiting
NCT07212361 — Infant Microbiota Restoration With Maternal Microbes · NA · recruiting
NCT07029360 — Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy · NA · recruiting
NCT06809660 — Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development (P · NA · recruiting
NCT07154173 — Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer · recruiting

Other Microbio Co Ltd trials

Trials by the same sponsor.

NCT05092464 — Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis · NA · unknown
NCT05078567 — Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Plaque Psoriasis · NA · unknown
NCT04909034 — A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembro · NA · completed
NCT04639492 — Postbiotic MBS and Metformin Combination in Patients With T2DM · NA · completed
NCT02135887 — A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer. · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04674839 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Microbio Co Ltd
Last refreshed: 23 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04674839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing